SynthesisMolecular biomedicine2025
Metabolomics and metabolites in cancer diagnosis and treatment.
Synthesis in Molecular biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- FABP4/5-Mediated Lipid Reprogramming Is Associated with Immunosuppressive T Cell Crosstalk in Cervical Cancer After Chemoradiotherapy.Biomedicines · 2026Article
- UPP1 in Cancer: Context-Dependent Roles in Metabolic Adaptation and Treatment Response.Current issues in molecular biology · 2026Review
- Integrated Elementomics-Genomics-Metabolomics Analysis Reveals Plasma Biomarker Networks and Diagnostic Potential for Gastric Cancer.Metabolites · 2026Article
- Liquid Biopsy-Based Metabolomics in Epithelial Ovarian Cancer: Challenges, Methodological Advances and Translational Considerations.Diagnostics (Basel, Switzerland) · 2026Review
- Glucose starvation induces fumarate hydratase succinylation and inhibits ferroptosis to maintain colon cancer cell proliferation.Cell death & disease · 2026Article
- Rewiring tumor metabolism: heterogeneity, oncometabolites, and adaptive plasticity.Experimental hematology & oncology · 2026Review
- A new era of precision diagnosis and treatment for lung cancer: artificial intelligence-driven multimodal data integration and clinical applications.Cell death & disease · 2026Review
- Metabolomic Profiling of Tyrosine Kinase Inhibitor-Induced Endothelial Dysfunction and Cardiovascular Toxicity.Metabolites · 2026Review
- Review
- Review
- Deep learning in multi-omics integration for gastrointestinal cancer biomarker discovery.Frontiers in oncology · 2026Review
- Unraveling role of arginine-NO metabolism by targeting HIF-1α signaling in mediating esophageal squamous cell carcinoma.Frontiers in molecular biosciences · 2026Article
- Causal associations between plasma metabolites and head and neck cancer: a bidirectional Mendelian randomization study.Brazilian journal of otorhinolaryngologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Cancer is a leading cause of death worldwide. Metabolic reprogramming in cancers plays an important role in tumor initiation, malignant progression and therapeutic response. Based on this, significant progress has been made in the development of the metabolite-based early cancer detection and targeted interventions. Over the past decade, metabolomics has been widely applied to detect metabolic alterations in tumor cells as well as their microenvironment. However, an up-to-date systematic review to summarize the current metabolomic and metabolites in cancer, especially their connections to cancer diagnostics/prognostic biomarkers and therapeutic strategies, is lacking. Here, we first introduced the platforms and analytical processes of metabolomics, as well as their application in different biological matrix of tumor patients. Then, we summarized representative cancer studies in which specific metabolites was found to be act as diagnostic or prognostic/stratification biomarkers. Furthermore, we reviewed the current therapeutic strategies targeting cancer metabolism, particularly the drugs/compounds that are either market-approved or in clinical trials, and also analyzed the potential of metabolites in personalizing precision treatment. Finally, we discussed the key challenges in this field, including the technical limitations of metabolomics and the clinical limitations of therapeutic targeting cancer metabolism, and further explored the future directions such as multi-omics perspective and lifestyle interventions. Taken together, we provides a comprehensive overview from technological platforms of metabolomics to translational applications of metabolites, facilitating the discovery of novel biomarkers and targeting strategies for precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.